275 related articles for article (PubMed ID: 12544410)
21. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.
Saitoh A; Singh KK; Powell CA; Fenton T; Fletcher CV; Brundage R; Starr S; Spector SA
AIDS; 2005 Mar; 19(4):371-80. PubMed ID: 15750390
[TBL] [Abstract][Full Text] [Related]
22. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.
Watson DC; Farley JJ
Pediatr Infect Dis J; 1999 Aug; 18(8):682-9. PubMed ID: 10462336
[TBL] [Abstract][Full Text] [Related]
24. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
[TBL] [Abstract][Full Text] [Related]
25. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
26. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
27. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.
Funk MB; Linde R; Wintergerst U; Notheis G; Hoffmann F; Schuster T; Kornhuber B; Ahrens P; Kreuz W
AIDS; 1999 Sep; 13(13):1653-8. PubMed ID: 10509566
[TBL] [Abstract][Full Text] [Related]
28. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.
Van Rossum AM; Gaakeer MI; Verweel S; Hartwig NG; Wolfs TF; Geelen SP; Lamberts SW; de Groot R
Pediatr Infect Dis J; 2003 Jan; 22(1):70-6. PubMed ID: 12544412
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
30. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
31. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome.
DeMasi RA; Graham NM; Tolson JM; Pham SV; Capuano GA; Fisher RL; Shaefer MS; Pakes GE; Sawyerr GA; Eron JJ
Adv Ther; 2001; 18(4):163-73. PubMed ID: 11697019
[TBL] [Abstract][Full Text] [Related]
32. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
33. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
[TBL] [Abstract][Full Text] [Related]
34. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
[TBL] [Abstract][Full Text] [Related]
35. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
36. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
[TBL] [Abstract][Full Text] [Related]
37. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus.
Shingadia D; Viani RM; Yogev R; Binns H; Dankner WM; Spector SA; Chadwick EG
Pediatrics; 2000 Jun; 105(6):E80. PubMed ID: 10835093
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
Kline MW; Brundage RC; Fletcher CV; Schwarzwald H; Calles NR; Buss NE; Snell P; DeLora P; Eason M; Jorga K; Craig C; Duff F
Pediatr Infect Dis J; 2001 Jul; 20(7):666-71. PubMed ID: 11465838
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
40. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]